E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.
Paprotka, Tobias, Venkatachari, Narasimhan J, Chaipan, Chawaree et al. · Journal of virology · 2010 · DOI
Quick Summary
This study investigated how a virus called XMRV, which has been found in some ME/CFS patients, survives and spreads in human cells. Researchers discovered that the virus can replicate more easily in certain cells that have low levels of natural antiviral proteins called APOBEC3. The study also found that some HIV medications (AZT, tenofovir, and raltegravir) can block XMRV replication in laboratory tests.
Why It Matters
Since XMRV has been detected in ME/CFS patient immune cells, understanding its replication strategy is critical for developing potential treatments. This work identifies specific cell types permissive to XMRV infection and demonstrates that existing antiretroviral drugs can inhibit the virus, suggesting potential therapeutic avenues worth investigating in clinical contexts.
Observed Findings
- Prostate cancer cell lines (LNCaP, DU145) expressed 50% lower A3F mRNA and nearly undetectable A3G compared to T-cell lines (CEM, H9).
- XMRV replication was inhibited in cells expressing high levels of APOBEC3G and APOBEC3F, with resulting G-to-A hypermutation of viral DNA.
- XMRV proviral genomes were extensively hypermutated in A3G/A3F-positive T cells but not in A3G/A3F-negative cells.
- The antiretroviral drugs zidovudine (AZT), tenofovir, and raltegravir all suppressed XMRV replication in vitro.
Inferred Conclusions
- XMRV infection may preferentially establish in cells with low or absent APOBEC3G/3F expression, such as certain prostate cancer cells.
- Existing anti-HIV drugs targeting reverse transcriptase and integrase may have activity against XMRV and warrant further investigation.
- APOBEC3 proteins represent an important innate antiviral mechanism that XMRV must evade to establish productive infection.
Remaining Questions
- Does XMRV expression of proteins that antagonize APOBEC3 (analogous to HIV Vif) exist, and if so, how does this affect the virus's ability to evade restriction?
- Are the APOBEC3 levels observed in this study consistent with XMRV detection patterns in actual ME/CFS and prostate cancer patient tissues?
What This Study Does Not Prove
This laboratory study does not prove that XMRV causes ME/CFS or that antiretroviral drugs would be clinically effective in ME/CFS patients. The presence of XMRV in patient cells does not establish causation, and in vitro drug susceptibility does not guarantee in vivo efficacy or safety in human treatment trials.
Tags
Symptom:Fatigue
Biomarker:Gene Expression
Method Flag:No ControlsExploratory Only
Metadata
- DOI
- 10.1128/JVI.00134-10
- PMID
- 20335265
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →